Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd (Nasdaq: IVVD) granted inducement stock options to four newly hired non-executive employees on March 1, 2026, totaling 192,000 shares under the 2026 Inducement Plan.

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) granted inducement stock options to four newly hired non-executive employees on March 1, 2026, totaling 192,000 shares under the 2026 Inducement Plan.

The options carry a $1.69 exercise price (closing price Feb 27, 2026), vest over four years (25% after one year, then monthly), have a 10-year term, and were granted under Nasdaq Listing Rule 5635(c)(4).

Argus Mar 3 session

-5.81% close to close Open Argus

Details

News Market Reaction – IVVD

In the Mar 3 session, IVVD declined 5.81%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.8% in the session following this news. A negative reaction despite the largely ro...

Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite the largely routine nature of inducement grants would fit a pattern where secondary factors influence trading. The award of 192,000 options at $1.69 under a 10-year term may highlight compensation and overhang concerns alongside an existing S-3 shelf. Past trading around news showed at least one sharp decline even on positive trial planning, suggesting sentiment can decouple from fundamentals.

Key Figures

Inducement option grants: 192,000 shares New hires: 4 employees Option exercise price: $1.69 per share +5 more

Inducement option grants

192,000 shares

Aggregate options to four new non-executive employees

New hires

4 employees

Non-executive employees receiving inducement options

Option exercise price

$1.69 per share

Set at Feb 27, 2026 closing price

Vesting period

4 years

Options vest over four years, service-based

Initial vesting cliff

25% after 1 year

First vesting on first anniversary of start date

Option term

10 years

Maximum life of each inducement option

Grant date

March 1, 2026

Date options were granted under inducement plan

Reference price date

February 27, 2026

Last trading day before grant used to set exercise price

Historical Context

5 past events · Latest: Feb 24

5 events

1. Feb 24

   Clinical publication

   24h Move

   +5.0%

   Peer-reviewed correlate-of-protection model for COVID-19 mAb across variants.

2. Feb 03

   Phase 3 planning

   24h Move

   +8.1%

   FDA alignment on LIBERTY Phase 3 trial comparing VYD2311 to mRNA vaccines.

3. Jan 22

   Marketing partnership

   24h Move

   +0.0%

   Education partnership with Lindsey Vonn to raise antibody awareness.

4. Jan 20

   Trial initiative

   24h Move

   -8.6%

   Planned Phase 2 study of VYD2311 for long COVID and vaccine-injured patients.

5. Jan 08

   Prelim earnings

   24h Move

   +4.6%

   Preliminary Q4 2025 PEMGARDA revenue growth and pipeline progress highlights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.69, representing the closing price of Invivyd’s common stock on February 27, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Invivyd (IVVD) announce about inducement option grants on March 1, 2026?

Invivyd granted options for an aggregate of 192,000 shares to four new non-executive hires. According to the company, grants were made under Nasdaq Listing Rule 5635(c)(4) and the Invivyd 2026 Inducement Plan to incentivize new employees.

What is the exercise price and term of the Invivyd (IVVD) inducement options granted March 1, 2026?

The options have a $1.69 per-share exercise price and a 10-year term. According to the company, $1.69 equals the closing price on Feb 27, 2026, the last trading day before the grant.

How do the Invivyd (IVVD) inducement options vest for the newly hired employees?

Each option vests over four years: 25% after the first anniversary, then monthly thereafter. According to the company, vesting is subject to each employee’s continuous service with Invivyd.

Under which plan and Nasdaq rule were Invivyd (IVVD) inducement options granted?

The grants were made under the Invivyd 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, this rule permits inducement awards for newly hired employees.

How many employees received inducement options from Invivyd (IVVD) and what was the total share amount?

Four newly hired non-executive employees received options totaling 192,000 shares. According to the company, the awards were intended as material inducements for each employee’s entry into employment.